←
Sid2,337 posts
Sid avatar

Sid

@mosasaurus27

Studying influenza and cell intrinsic immunity @BiochemOxford (Masters student)

◷ Joined March 2020▧ 40 Photos and videos
Sid avatar
Sid@mosasaurus27·Oct 8

Pioneers get slaughtered; settlers get rich. How does this play out in pharma? I got chatty to sketch 3 graphs. First: Among the top 20 most valuable drug target franchises, who was the pioneer and who is taking the lion's share of revenue?

Post attachment
News from Science avatar
⟳ Sid retweeted
News from Science@NewsfromScience·Nov 15

Tinnitus—a constant ringing or buzzing in the ears that affects about 15% of people—is difficult to understand and even harder to treat. In 2020, scientists found that shocking the tongue—combined with a carefully designed sound program—can reduce symptoms of the disorder, not just while patients are being treated, but up to 1 year later. Learn more: scim.ag/48aGMQX #ScienceMagArchives

Post attachment
Sid avatar
Sid@mosasaurus27·Nov 15

Every British, university spin-out Biotech has the same website

Marios Georgakis avatar
⟳ Sid retweeted
Marios Georgakis@MariosGeorgakis·Nov 2

Last week, asundexian became the first factor XIa inhibitor to receive regulatory approval for secondary stroke prevention in patients with non-cardioembolic stroke (in China). F11 is a genetically well-validated target for stroke, and human genetic evidence has likely helped accelerate clinical development of factor XIa inhibitors in this space. Interestingly, however, the genetic association signal for F11 has consistently been strongest for cardioembolic stroke. Yet asundexian failed to demonstrate benefit over existing, more potent anticoagulant options for cardioembolic stroke prevention in patients with atrial fibrillation. Instead, in the OCEANIC-STROKE trial, asundexian reduced recurrent stroke risk on top of antiplatelet therapy across all non-cardioembolic ischemic stroke subtypes. A great example of how the translation of human genetic findings into clinical trial outcomes is rarely 1:1. Clinical development is nuanced and depends on other factors beyond causal biology.

Post attachment
Sid avatar
Sid@mosasaurus27·Nov 13

Broad spectrum antivirals for farm animals must be at the forefront of biosecurity program priorities. It isn’t as flashy as AI viruses but it certainly poses a far greater and historically relevant threat to human health I think host directed antivirals are the correct approach for this. You can target pathways within the cell that are essential for the virus, and establish a significant hurdle for the pathogen that it cannot mutate out of.

It’s just a matter of time, people. We need to roll out an H5N1 cow vaccine as a public health matter. There’s a fresh pandemic cooking in our backyard - government action now to vaccinate cattle could avert a future pandemic. telegraph.co.uk/global-healt…

Sid avatar
Sid@mosasaurus27·Nov 13

Interesting. I like this Roviant/BridgeBio inspired design in pharma. TrialSpark also has years of experience doing the very thing that they differentiate themselves with from other hub-spoke models. They’re actually focusing on the real issues in biotech!

𝐅𝐫𝐨𝐦 𝐍𝐘𝐒𝐄: @formationbio announced a $600M fund it will use to acquire 10–15 drug programs over the next 3–5 years - a step in its plan to make drug development more efficient and become 'the next pharma'. @BenjamineYLiu Watch the full video: biotechtv.com/post/formation…

5:01
Sid avatar
Sid@mosasaurus27·Nov 11

Is this another Adaptyv basically

Today we're launching Petrichor (YC F26), a wet lab for frontier AI labs. We run experiments in parallel and return the data from every step.

0:45
John Evans avatar
⟳ Sid retweeted
John Evans@john_evans3·Nov 10

Positive data for risto-cel in sickle cell disease! In the BEACON trial, risto-cel met the primary efficacy endpoint of freedom from severe VOCs for at least 12 consecutive months (VF12), all primary safety endpoints, and all secondary efficacy endpoints globenewswire.com/news-relea…

Sid avatar
Sid@mosasaurus27·Nov 8

Has Alpha-Fold really not led to drug development? I find this very hard to believe…

You may find this hard to believe, but for all of the papers and announcements in science and health from, from @GoogleDeepMind , 🔺 NONE are routinely used in real life 🔺Oh, but Alpha-Fold (discussed frequently; had not led to actual drug development), “In short, the strongest “routinely used” examples so far are in specialized genomics analysis and research support, with clinical pilots and screening evaluations for imaging and conversational AI. Direct, widespread bedside or standard-of-care deployment.””

Chris Croy avatar
⟳ Sid retweeted
Chris Croy@ChrisCroy·Nov 7

Pfizer lost over a billion dollars on their inhaled insulin product, Exubera. There were a bunch of problems with it (most importantly that it cost twice as much as other forms of insulin) but the funniest was that patients really didn't like using it in public. You popped a cartridge into it, the clear chamber filled with white "smoke", and then you cleared it one breath. It looked exactly like you were smoking weed out of your Pfibong. There's still an inhaled insulin product on the market, Afrezza, which looks like a weird vape.

Post attachmentPost attachment

Why are bongs only used for drugs? The weird shapes? I want to make a straight, white, clinical style bong for normal people with normal medicines.

Daisuke Kihara avatar
⟳ Sid retweeted
Daisuke Kihara@d_kihara·Nov 7

クライオEM構造解析を自律的に進めるAIシステム、CryoPilotを開発しました。 2つのエージェントがCryoSPARCによる3次元再構成と、CryoZeta・DAQによる原子モデル構築・検証を担当します。中間結果を評価し、解析戦略を選択・修正、実行します。 doi.org/10.64898/2026.10.29.… cryopilot.vercel.app/

Post attachmentPost attachment
Sid avatar
Sid@mosasaurus27·Nov 8

It remains stable throughout life. That means a consistent level of high exposure for those who carry certain KIV2 alleles. Interventions that start earlier in life are probably effective!

so...does LP(a) not matter?